The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial

Trials

Ke Jiang¹  Lei Wang¹  Xinyue Zhang¹  Yajie Ji¹  Yuanyuan Feng¹  Xiaohong Xue¹  Qiong Li¹  Weili Chen¹  Minhong Wang¹  Shanyan Sha¹  Peiyi Zheng¹  Hongli Liang¹  Siyu Li¹  Mengting Li¹  Jiayu Sheng¹  Zongxin Chen¹  Qing Lu¹  Yu Liu¹  Zhiguang Yin²  Huangan Wu²  Yan Huang²  Huirong Liu² 

[1] Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 200437, Shanghai, China;Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, 200030, Shanghai, China;

关键词: Breast cancer;    Traditional Chinese medicine;    Wenshen Shengbai decoction;    Moxibustion;    Chemotherapy-induced myelosuppression;   

DOI  :  10.1186/s13063-020-04749-6

来源: Springer

【 摘 要 】

BackgroundTraditional Chinese medicine (TCM) has a long history of use in breast cancer, but lacking systematic evidence to support its clinical benefits. In this study, we evaluated the prophylactic and therapeutic effects of moxibustion combined with decoctions for treating chemotherapy-induced myelosuppression (CIM) in early-stage breast cancer patients.MethodsThis is a randomized controlled clinical trial single-blinded for TCM decoction but not moxibustion. Patients are equally divided into the control group without decoction and moxibustion treatment (control), the decoction+moxibustion group (MD), and the placebo+moxibustion group (MP), according to the following stratification factors: age (below 40s, 40s, 50s, and 60s or above), chemotherapy regimen (anthracyclines, taxanes, anthracyclines+taxane, and others), and chemotherapy strategy (adjuvant and neoadjuvant). The TCM decoction is Wenshen Shengbai Decoction. The anticipated sample size is 462 cases (154 cases in each group). All participants are expected to treat with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF). The primary outcomes include the proportion of patients with relief of leukopenia and/or neutropenia, the myelosuppression-associated serious adverse event including grade 3–4 leukopenia and/or neutropenia, and febrile neutropenia, and the dose of rhG-CSF. The secondary outcomes include chemotherapy adherence, stratified analysis, adverse reactions, quality of life by EORTC Breast-Cancer-Specific Quality of Life Questionnaire including EORTC QLQ-C30 (V3.0) and QLQ-BR23, TCM Constitution, and 3-year disease-free survival and overall survival. Baseline information including age, surgical approach, chemotherapy regimen and strategy, pathological stage, and molecular subtype will be recorded.DiscussionThis will be the first randomized controlled trial to evaluate the efficacy of moxibustion combined with TCM decoction in treating CIM in early-stage breast cancer patients, aiming to standardize the TCM decoction and moxibustion method, thus providing evidence for its clinical benefit.Trial registrationchictr.org.cn ChiCTR-INR-16009557. Registered on 23 October 2016.

【 授权许可】

CC BY